Increasing Cases Of Cushings Disease To Boost The Cushings Syndrome Market Growth

Cushings Syndrome Market
Cushings Syndrome Market

Cushings Syndrome Market, By Treatment Type (Surgery, Radiation Therapy, Drugs, Others), Diagnosis (Petrosal Sinus Sampling, Saliva Test, Urine and Blood Tests, Imaging Tests), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

The global Cushings Syndrome Market is estimated to be valued at US$ 333.80 million in 2021 and is expected to exhibit a CAGR of 9.44 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Cushings Syndrome is also known as hypercortisolism is a problem that leads too much cortisol to be prepared. It impacts the master and adrenal glands. It generally takes place in kids and can lead to the difficulties in development, obesity, and other prodromes. The most general problem of Cushings syndrome is an irregularity in the pituitary gland.

This is the gland that usually makes the hormone adrenocorticotropic hormone. If one have a pituitary cancer, one might require operation to detach it. One will also require to consume drugs to decrease the amount of cortisol levels in the body. The supplier might order imagery methods to monitor for cancer in the master or adrenal glands.

Competitive Landscape:

Key players involved in the growth of global Cushings Syndrome Market are Strongbridge Biopharma, CORCEPT THERAPEUTICS, Novartis and HRA Pharma.

Market Key Drivers:

Increasing cases of cushings disease is expected to boost the growth of global Cushings Syndrome for Market. For instance, as per UCLA, around 10 to 15 people per million suffer from cushings disease.

The expansion of the worldwide Somatropin Market is anticipated to be driven by the growing long-term effects of growth hormone treatment on children with growth hormone insufficiency.

Rising elderly population is projected to propel the growth of global Cushings Syndrome for Market. For instance, as per WHO, around 1 in 6 people would be 60 years or above across the globe by 2030.

Covid-19 Impact Analysis:

The Covid-19 outbreak has adversely affected the growth of global Cushings Syndrome for Market due to the imposition of strict lockdown. The surge in cases has led to the delay in the treatment of others disease. The pandemic has led to the disruption in expansion of healthcare infrastructure and interrupted the supply chain.

Key Takeaways:

The global Cushings Syndrome Market is anticipated to exhibit a CAGR of 9.44 % during the forecast period owing to the rising product approvals and launches. For instance, in March 2020, the U.S. FDA approved Isturisa oral medicines for adults living with Cushing's disease.

Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in global Cushings Syndrome for Market due to rise in cushings syndrome, rising R&D, rising investment in infrastructure and increasing geriatric population. For instance, as per NORD, around 13 per million people suffered from cushings syndrome in U.S.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more